NCT00841594 is a Phase 1 clinical trial of nitroglycerin 0.9 % (MXQ-503) in Raynaud's Phenomenon, sponsored by MediQuest Therapeutics.

Who is sponsoring NCT00841594?

NCT00841594 is sponsored by MediQuest Therapeutics.

What drugs are being tested in NCT00841594?

Interventions in NCT00841594: nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP.

What condition does NCT00841594 study?

NCT00841594 studies Raynaud's Phenomenon.

Is NCT00841594 still recruiting?

NCT00841594 is currently completed. Last updated 13 May 2011.

Last reviewed 2011-05-13 · How we verify

NCT00841594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects

Completed Phase 1 Last updated 13 May 2011

What this trial tests

Phase 1 trial testing nitroglycerin 0.9 % (MXQ-503) in Raynaud's Phenomenon in 12 participants. Completed in 1 March 2009.

Timeline

1 February 2009

Primary endpoint
1 February 2009

1 March 2009

Quick facts

Lead sponsor	MediQuest Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 February 2009
Primary completion	1 February 2009
Estimated completion	1 March 2009
Sites	1 location across United States

Drugs / interventions tested

nitroglycerin 0.9 % (MXQ-503) — full drug profile →
Nitroglycerin ointment 2%, USP — full drug profile →

Conditions studied

Raynaud's Phenomenon — all drugs for Raynaud's Phenomenon →

Sponsor

MediQuest Therapeutics — full company profile →

Who can join

Adults 18 to 50, any sex, with Raynaud's Phenomenon. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measurement and comparison of the levels of nitroglycerin and its dinitrate metabolites in the blood of healthy human volunteers after a single topical dose of MQX 503 and a single topical dose of Nitroglycerin Ointment 2%, USP.
Time frame: 12 hours

Sponsor's own description

The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00841594 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MediQuest Therapeutics
Last refreshed: 13 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00841594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing